POINT Biopharma Global Inc


POINT Biopharma Global Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.85
  • Today's Change-0.43 / -5.91%
  • Shares traded691.87k
  • 1 Year change+1.93%
  • Beta--
Data delayed at least 15 minutes, as of Mar 22 2023 20:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company, through its subsidiaries is focused on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's clinical-stage product candidates include PNT2003 and PNT2002 for the treatment of prostate cancer and neuroendocrine tumors. Its preclinical stage product candidates include Lu-PNT2004 and Lu-PNT2001. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2004 is a family of fibroblast activation protein-alpha (FAP-alpha), which targeted radioligands. PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-79.17m
  • Incorporated2020
  • Employees72.00
  • Location
    POINT Biopharma Global Inc4850 West 78Th Street, 18Th FloorINDIANAPOLIS 46268United StatesUSA
  • Phone+1 (317) 543-9957
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pointbiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
ANI Pharmaceuticals Inc316.39m-49.52m697.54m600.00--2.2268.852.20-3.05-3.0519.4619.340.41311.482.15527,308.30-6.25-3.38-7.12-4.0856.1359.73-15.14-7.962.40-1.050.4584--46.3812.34-15.72---3.06--
Arcutis Biotherapeutics Inc3.69m-311.46m706.12m268.00--3.37--191.57-5.65-5.650.0673.430.0086--0.835813,753.73-72.65-65.51-79.22-70.9179.54---8,449.76-19,390.7511.37-19.270.4855-------50.93------
Ideaya Biosciences Inc50.93m-58.66m707.91m103.00--2.02--13.90-1.40-1.401.227.250.1324--77.52494,475.70-15.25-20.08-16.94-22.40-----115.17-222.78----0.00--82.28---17.87--14.40--
Anavex Life Sciences Corp0.00-50.07m710.09m38.00--5.26-----0.6463-0.64630.001.730.00----0.00-32.80-46.07-35.57-51.22------------0.00-------26.56------
IGM Biosciences Inc697.00k-219.17m731.05m242.00--2.23--1,048.85-5.68-5.680.01797.670.0016----3,630.21-50.20---54.23-------31,444.48------0.00-------103.02------
Viking Therapeutics Inc0.00-68.87m735.57m21.00--5.05-----0.8964-0.89640.001.860.00----0.00-36.32-18.38-39.53-19.17------------0.00-------25.24------
Cogent Biosciences Inc0.00-140.24m763.12m138.00--4.02-----2.45-2.450.003.660.00----0.00-52.63-44.58-57.36-50.10-------881.92----0.00-------94.04--49.73--
Seres Therapeutics Inc7.13m-250.16m767.81m431.00--70.72--107.72-2.36-2.360.0660.08610.0203----16,538.28-71.10-47.06-93.38-60.78-----3,509.50-231.45---83.220.8256---95.08-25.99-281.46--16.00--
POINT Biopharma Global Inc0.00-79.17m769.09m72.00--2.45-----0.8713-0.87130.002.970.00----0.00-26.26---27.39--------------0.00-------243.25------
Innoviva Inc331.34m213.92m771.87m101.004.851.363.302.332.332.333.488.310.3071--3.793,280,584.0020.4137.0223.1140.2536.00--66.4893.572.871.270.4885---15.458.81-19.539.78----
Allogene Therapeutics Inc243.00k-332.63m774.51m359.00--1.16--3,187.27-2.32-2.320.00174.610.0003----676.88-35.85-29.66-37.95-31.41-----136,885.60-3,191.05----0.00---99.37---29.43------
Kiniksa Pharmaceuticals Ltd220.18m183.36m789.61m220.004.381.994.253.592.592.593.155.680.63591.8118.121,000,818.0052.96-28.4061.06-32.5289.60--83.28-155.014.71--0.00--471.24--216.11--8.76--
Exscientia PLC (ADR)29.99m-121.81m797.13m287.00--1.28--26.58-1.00-1.000.24665.080.05154.936.25104,479.00-20.32---23.43---16.44---406.22--7.55--0.013--182.87---120.94------
Immunitybio Inc240.00k-416.57m801.94m725.00------3,341.41-1.04-1.040.0006-1.060.0006--0.1489331.03-100.41-94.40---212.70-----173,883.30-30,976.64---5.482.97---74.3039.77-20.12--23.34--
ARS Pharmaceuticals Inc0.00-85.38m807.32m92.00--1.14-----2.43-2.430.007.440.00----0.00-27.38---28.26--------------0.00-------171.58------
Data as of Mar 22 2023. Currency figures normalised to POINT Biopharma Global Inc's reporting currency: US Dollar USD

Institutional shareholders

39.02%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 31 Dec 20229.18m8.69%
BlackRock Fund Advisorsas of 31 Dec 20224.89m4.63%
PFM Health Sciences LPas of 31 Dec 20224.63m4.39%
SSgA Funds Management, Inc.as of 31 Dec 20224.29m4.06%
The Vanguard Group, Inc.as of 31 Dec 20224.19m3.96%
Citadel Advisors LLCas of 31 Dec 20223.25m3.07%
Point72 Asset Management LPas of 31 Dec 20223.20m3.03%
Suvretta Capital Management LLCas of 31 Dec 20222.63m2.49%
Great Point Partners LLCas of 31 Dec 20222.54m2.41%
Avidity Partners Management LPas of 31 Dec 20222.43m2.30%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.